teva report non-gaap ep revenu compar street
estim respect beyond upward guidanc revis
manag guid approv fremanezumab migrain prophylaxi
end expect continu believ may overli optimist
though manag make progress regard streamlin cost structur still
good deal confid trough year ebitda/ep
given backdrop net ebitda ebitda
believ downsid risk upsid potenti share reiter
underweight rate rais pt owe upward estim
revis slower pace copaxon eros henc slightli higher margin
detail updat guidanc revis realli us
new ebitda guidanc rang versu prior rang
reflect somewhat slower eros copaxon teva share copaxom mg/
ml volum stand versu earli per im addit cost cut
captur new rang reflect major chang manag
think regard gener landscap still rel dearth
higher-valu gener shots-on-go teva launch viagra gener
exclus last decemb teva entri lialda market last month
third entrant two notabl except manag continu appropri
focus reduc exposur low-margin unprofit gener though
mean posit gener busi stabil given dearth
major launch price pressur even price eros moder
approv guidanc fremanezumab still look gener teva expect
approv fda action date expect pre-approv inspect
pai go hand-in-hand broader inspect celltrion facil notabl
believ complet come month enabl launch
end would take cautiou view bear mind come
remedi warn letter timeli tend except rather
rule still could see approv next year
latest color austedo austedo sale compar sale
note neurocrin report ingrezza sale recal
ingrezza austedo launch ingrezza indic tardiv
dyskinesia td wherea austedo indic td huntington chorea
continu believ ingrezza signific competit advantag given
absenc oner titrat once-daili dose profil remain
cautiou austedo long-term sale potenti
risk includ copaxon competit gener price risk
teva world largest gener manufactur leader neurolog drug
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
note street estim
compani report factset research pjc estim
compani report pjc estim
page
million except per share itemsactualspjc estimatesstreet estimatesnorth america market non-cor except per
note prior estim comparison may applic due pjc updat report line item
reflect singl copaxon mg gener entrant start addit entrant time-frame
consensu estim
compani report factset research pjc estim
page
million except per america market pharmaceut non-cor consensu incom expens net share consensu teva quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
cog product revenu
expens total revenu
sell gener administr
sell gener administr
reflect singl copaxon mg gener entrant start addit entrant time-frame
teva close acquisit anda segment earli octob reflect full quarter contribut anda
teva alter revenu report methodolog result histor may reflect pjc estim
proprietari piper jaffray may
page
million
net chang asset liabil
acquisit intang
stock option issuanc
proprietari piper jaffray may
page
million
properti plant equip net
asset defer charg
proprietari piper jaffray may
page
